Research graph
References from Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Understanding and targeting prostate cancer cell heterogeneity and plasticity
10.1016/j.semcancer.2021.11.001 · 2022 · External reference
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
10.1001/jama.294.4.433 · 2005 · External reference
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
10.1038/nrc4016 · 2015 · External reference
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
10.1172/jci128212 · 2019 · External reference
Neuroendocrine differentiation in prostate cancer: Emerging biology, models, and therapies
10.1101/cshperspect.a030593 · 2019 · External reference
The long tail of oncogenic drivers in prostate cancer
10.1038/s41588-018-0078-z · 2018 · External reference
Genomic correlates of clinical outcome in advanced prostate cancer
10.1073/pnas.1902651116 · 2019 · External reference
Novel signatures of prostate cancer progression and therapeutic resistance
10.1080/14728222.2023.2293757 · 2023 · External reference
Application of prostate cancer models for preclinical study: Advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells
10.3390/cells8010074 · 2019 · External reference
Cancer cell lines for drug discovery and development
10.1158/0008-5472.can-13-2971 · 2014 · External reference
Patient-derived xenograft models: an emerging platform for translational cancer research
10.1158/2159-8290.cd-14-0001 · 2014 · External reference
Current experimental human tissue-derived models for prostate cancer research
10.1111/iju.14441 · 2021 · External reference
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy
10.1002/cac2.12224 · 2021 · External reference
A PDX/Organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening
10.1158/1078-0432.ccr-18-0409 · 2018 · External reference
Patient derived organoids to model rare prostate cancer phenotypes
10.1038/s41467-018-04495-z · 2018 · External reference
Anchorage-independent culture maintains prostate stem cells
10.1016/j.ydbio.2007.09.042 · 2007 · External reference
Organoid culture systems for prostate epithelial and cancer tissue
10.1038/nprot.2016.006 · 2016 · External reference
Isolation, cultivation and characterization of adult murine prostate stem cells
10.1038/nprot.2010.11 · 2010 · External reference
Identification of multipotent luminal progenitor cells in human prostate organoid cultures
10.1016/j.cell.2014.08.017 · 2014 · External reference
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
10.1038/nature07935 · 2009 · External reference
ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells
10.1016/j.ajpath.2011.10.036 · 2012 · External reference
Organoid cultures derived from patients with advanced prostate cancer
10.1016/j.cell.2014.08.016 · 2014 · External reference
Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay
10.1073/pnas.1603645113 · 2016 · External reference
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair
10.1093/annonc/mdx165 · 2017 · External reference
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
10.1126/science.abe1505 · 2022 · External reference
Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer
10.3892/ol.2021.13124 · 2022 · External reference
Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease
10.1002/1878-0261.13382 · 2023 · External reference
Generation of prostate cancer assembloids modeling the patient-specific tumor microenvironment
10.1371/journal.pgen.1011652 · 2025 · External reference
Extracellular matrix in synthetic hydrogel-based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors
10.1002/adma.202100096 · 2022 · External reference
Spherical cancer models in tumor biology
10.1016/j.neo.2014.12.004 · 2015 · External reference
Microwell-based flow culture increases viability and restores drug response in prostate cancer spheroids
10.1002/biot.202200434 · 2023 · External reference
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341
2000 · External reference
3D cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer
10.1371/journal.pone.0111029 · 2014 · External reference
The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform
10.1038/s41598-017-18050-1 · 2018 · External reference
Modeling cell communication in cancer with organoids: Making the complex simple
10.3389/fcell.2020.00166 · 2020 · External reference
Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and Malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens
10.1158/0008-5472.can-06-4429 · 2007 · External reference
Single luminal epithelial progenitors can generate prostate organoids in culture
10.1038/ncb3047 · 2014 · External reference
A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses
10.1371/journal.pone.0010431 · 2010 · External reference
Tumor clone dynamics in lethal prostate cancer
10.1126/scitranslmed.3009448 · 2014 · External reference
NSD2 targeting reverses plasticity and drug resistance in prostate cancer
10.1038/s41586-025-09727-z · 2026 · External reference
FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity
10.1016/j.celrep.2026.116950 · 2026 · External reference
Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer
10.1016/j.cell.2018.04.034 · 2018 · External reference
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
10.1016/j.xcrm.2024.101758 · 2024 · External reference
Epigenetic derepression of PROX1 promotes neuroendocrine prostate cancer progression
10.1158/0008-5472.can-25-0636 · 2025 · External reference
Prostate cancer stroma: an important factor in cancer growth and progression
10.17305/bjbms.2015.449 · 2015 · External reference
A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions
10.1016/j.biomaterials.2015.10.059 · 2016 · External reference
Cancer-associated fibroblasts modify the response of prostate cancer cells to androgen and anti-androgens in three-dimensional spheroid culture
10.3390/ijms17091458 · 2016 · External reference
Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis
10.1186/s12964-019-0505-5 · 2020 · External reference
Prostate stroma increases the viability and maintains the branching phenotype of human prostate organoids
10.1016/j.isci.2019.01.028 · 2019 · External reference
Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models
10.1002/cam4.70240 · 2024 · External reference
Bioengineered tumor-stroma prostate cancer in vitro models for screening therapeutics
10.1002/bit.28971 · 2025 · External reference
Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers
10.1002/bit.28971 · 2023 · External reference
Dual-mTOR inhibitor Rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity
10.3389/fonc.2020.01012 · 2020 · External reference
PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition
10.1126/sciadv.ade8641 · 2023 · External reference
Application of organoid models in prostate cancer research
10.3389/fonc.2021.736431 · 2021 · External reference
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer
10.1038/s41598-018-35417-0 · 2018 · External reference
Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening
10.1080/07853890.2025.2602324 · 2025 · External reference
Integrative clinical genomics of advanced prostate cancer
10.1016/j.cell.2015.05.001 · 2015 · External reference
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade
10.1016/j.cell.2013.11.012 · 2013 · External reference
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
10.1126/science.aah4199 · 2017 · External reference
Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations
10.15252/msb.20177697 · 2017 · External reference
Prostate organoid cultures as tools to translate genotypes and mutational profiles to pharmacological responses
10.3791/60346 · 2019 · External reference
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
10.1038/nm.4378 · 2017 · External reference
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer
10.15252/emmm.201910659 · 2019 · External reference
Targeting cancer drug resistance utilizing organoid technology
10.1016/j.biopha.2022.114098 · 2023 · External reference
Novel dormancy mechanism of castration resistance in bone metastatic prostate cancer organoids
10.3390/ijms23063203 · 2022 · External reference
An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence
10.1016/j.ccell.2020.12.002 · 2021 · External reference
Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
10.1038/s43018-022-00431-9 · 2022 · External reference
A phase II trial of the Aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers
10.1158/1078-0432.ccr-18-1912 · 2019 · External reference
A patient-derived organoid platform from TUR-P samples enables precision drug screening in advanced prostate cancer
10.3390/cancers17243973 · 2025 · External reference
Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer
10.1016/j.ccell.2020.06.005 · 2020 · External reference
Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens
10.1002/path.5698 · 2021 · External reference
Prostate organoids: emerging experimental tools for translational research
10.1172/jci169616 · 2023 · External reference
Stromal-epithelial interactions and heterogeneity of proliferative activity within the prostate
10.1139/o86-084 · 1986 · External reference
Distribution of metastatic sites in patients with prostate cancer: a population-based analysis
10.1002/pros.22742 · 2014 · External reference
Metastases in prostate cancer
10.1101/cshperspect.a033688 · 2019 · External reference
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
10.1038/s41568-024-00706-6 · 2024 · External reference
Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids
10.1016/j.cell.2018.07.009 · 2018 · External reference
Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
10.1136/jitc-2021-003213 · 2021 · External reference
Engineering vascularized brain tumor organoids: bridging the gap between models and reality
10.1007/s10544-025-00773-y · 2025 · External reference
Modelling the tumor immune microenvironment for precision immunotherapy
10.1002/cti2.1400 · 2022 · External reference
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
10.1001/jama.294.4.433 · ExternalCitation · doi-reference
Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease
10.1002/1878-0261.13382 · ExternalCitation · doi-reference
Extracellular matrix in synthetic hydrogel-based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors
10.1002/adma.202100096 · ExternalCitation · doi-reference
Microwell-based flow culture increases viability and restores drug response in prostate cancer spheroids
10.1002/biot.202200434 · ExternalCitation · doi-reference
Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers
10.1002/bit.28971 · ExternalCitation · doi-reference
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy
10.1002/cac2.12224 · ExternalCitation · doi-reference
Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models
10.1002/cam4.70240 · ExternalCitation · doi-reference
Modelling the tumor immune microenvironment for precision immunotherapy
10.1002/cti2.1400 · ExternalCitation · doi-reference
Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens
10.1002/path.5698 · ExternalCitation · doi-reference
Distribution of metastatic sites in patients with prostate cancer: a population-based analysis
10.1002/pros.22742 · ExternalCitation · doi-reference
Engineering vascularized brain tumor organoids: bridging the gap between models and reality
10.1007/s10544-025-00773-y · ExternalCitation · doi-reference
ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells
10.1016/j.ajpath.2011.10.036 · ExternalCitation · doi-reference
A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions
10.1016/j.biomaterials.2015.10.059 · ExternalCitation · doi-reference
Targeting cancer drug resistance utilizing organoid technology
10.1016/j.biopha.2022.114098 · ExternalCitation · doi-reference
Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer
10.1016/j.ccell.2020.06.005 · ExternalCitation · doi-reference
An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence
10.1016/j.ccell.2020.12.002 · ExternalCitation · doi-reference
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade
10.1016/j.cell.2013.11.012 · ExternalCitation · doi-reference
Organoid cultures derived from patients with advanced prostate cancer
10.1016/j.cell.2014.08.016 · ExternalCitation · doi-reference
Identification of multipotent luminal progenitor cells in human prostate organoid cultures
10.1016/j.cell.2014.08.017 · ExternalCitation · doi-reference
Integrative clinical genomics of advanced prostate cancer
10.1016/j.cell.2015.05.001 · ExternalCitation · doi-reference
Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer
10.1016/j.cell.2018.04.034 · ExternalCitation · doi-reference
Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids
10.1016/j.cell.2018.07.009 · ExternalCitation · doi-reference
FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity
10.1016/j.celrep.2026.116950 · ExternalCitation · doi-reference
Prostate stroma increases the viability and maintains the branching phenotype of human prostate organoids
10.1016/j.isci.2019.01.028 · ExternalCitation · doi-reference
Spherical cancer models in tumor biology
10.1016/j.neo.2014.12.004 · ExternalCitation · doi-reference
Understanding and targeting prostate cancer cell heterogeneity and plasticity
10.1016/j.semcancer.2021.11.001 · ExternalCitation · doi-reference
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
10.1016/j.xcrm.2024.101758 · ExternalCitation · doi-reference
Anchorage-independent culture maintains prostate stem cells
10.1016/j.ydbio.2007.09.042 · ExternalCitation · doi-reference
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
10.1038/nature07935 · ExternalCitation · doi-reference
Single luminal epithelial progenitors can generate prostate organoids in culture
10.1038/ncb3047 · ExternalCitation · doi-reference
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
10.1038/nm.4378 · ExternalCitation · doi-reference
Isolation, cultivation and characterization of adult murine prostate stem cells
10.1038/nprot.2010.11 · ExternalCitation · doi-reference
Organoid culture systems for prostate epithelial and cancer tissue
10.1038/nprot.2016.006 · ExternalCitation · doi-reference
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
10.1038/nrc4016 · ExternalCitation · doi-reference
Patient derived organoids to model rare prostate cancer phenotypes
10.1038/s41467-018-04495-z · ExternalCitation · doi-reference
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
10.1038/s41568-024-00706-6 · ExternalCitation · doi-reference
NSD2 targeting reverses plasticity and drug resistance in prostate cancer
10.1038/s41586-025-09727-z · ExternalCitation · doi-reference
The long tail of oncogenic drivers in prostate cancer
10.1038/s41588-018-0078-z · ExternalCitation · doi-reference
The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform
10.1038/s41598-017-18050-1 · ExternalCitation · doi-reference
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer
10.1038/s41598-018-35417-0 · ExternalCitation · doi-reference
Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
10.1038/s43018-022-00431-9 · ExternalCitation · doi-reference
Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay
10.1073/pnas.1603645113 · ExternalCitation · doi-reference
Genomic correlates of clinical outcome in advanced prostate cancer
10.1073/pnas.1902651116 · ExternalCitation · doi-reference
Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening
10.1080/07853890.2025.2602324 · ExternalCitation · doi-reference
Novel signatures of prostate cancer progression and therapeutic resistance
10.1080/14728222.2023.2293757 · ExternalCitation · doi-reference
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair
10.1093/annonc/mdx165 · ExternalCitation · doi-reference
Neuroendocrine differentiation in prostate cancer: Emerging biology, models, and therapies
10.1101/cshperspect.a030593 · ExternalCitation · doi-reference
Metastases in prostate cancer
10.1101/cshperspect.a033688 · ExternalCitation · doi-reference
Current experimental human tissue-derived models for prostate cancer research
10.1111/iju.14441 · ExternalCitation · doi-reference
PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition
10.1126/sciadv.ade8641 · ExternalCitation · doi-reference
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
10.1126/science.aah4199 · ExternalCitation · doi-reference
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
10.1126/science.abe1505 · ExternalCitation · doi-reference
Tumor clone dynamics in lethal prostate cancer
10.1126/scitranslmed.3009448 · ExternalCitation · doi-reference
Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
10.1136/jitc-2021-003213 · ExternalCitation · doi-reference
Stromal-epithelial interactions and heterogeneity of proliferative activity within the prostate
10.1139/o86-084 · ExternalCitation · doi-reference
Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and Malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens
10.1158/0008-5472.can-06-4429 · ExternalCitation · doi-reference
Cancer cell lines for drug discovery and development
10.1158/0008-5472.can-13-2971 · ExternalCitation · doi-reference
Epigenetic derepression of PROX1 promotes neuroendocrine prostate cancer progression
10.1158/0008-5472.can-25-0636 · ExternalCitation · doi-reference
A PDX/Organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening
10.1158/1078-0432.ccr-18-0409 · ExternalCitation · doi-reference
A phase II trial of the Aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers
10.1158/1078-0432.ccr-18-1912 · ExternalCitation · doi-reference
Patient-derived xenograft models: an emerging platform for translational cancer research
10.1158/2159-8290.cd-14-0001 · ExternalCitation · doi-reference
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
10.1172/jci128212 · ExternalCitation · doi-reference
Prostate organoids: emerging experimental tools for translational research
10.1172/jci169616 · ExternalCitation · doi-reference
Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis
10.1186/s12964-019-0505-5 · ExternalCitation · doi-reference
Generation of prostate cancer assembloids modeling the patient-specific tumor microenvironment
10.1371/journal.pgen.1011652 · ExternalCitation · doi-reference
A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses
10.1371/journal.pone.0010431 · ExternalCitation · doi-reference
3D cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer
10.1371/journal.pone.0111029 · ExternalCitation · doi-reference
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer
10.15252/emmm.201910659 · ExternalCitation · doi-reference
Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations
10.15252/msb.20177697 · ExternalCitation · doi-reference
Prostate cancer stroma: an important factor in cancer growth and progression
10.17305/bjbms.2015.449 · ExternalCitation · doi-reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · ExternalCitation · doi-reference
Modeling cell communication in cancer with organoids: Making the complex simple
10.3389/fcell.2020.00166 · ExternalCitation · doi-reference
Dual-mTOR inhibitor Rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity
10.3389/fonc.2020.01012 · ExternalCitation · doi-reference
Application of organoid models in prostate cancer research
10.3389/fonc.2021.736431 · ExternalCitation · doi-reference
A patient-derived organoid platform from TUR-P samples enables precision drug screening in advanced prostate cancer
10.3390/cancers17243973 · ExternalCitation · doi-reference
Application of prostate cancer models for preclinical study: Advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells
10.3390/cells8010074 · ExternalCitation · doi-reference
Cancer-associated fibroblasts modify the response of prostate cancer cells to androgen and anti-androgens in three-dimensional spheroid culture
10.3390/ijms17091458 · ExternalCitation · doi-reference
Novel dormancy mechanism of castration resistance in bone metastatic prostate cancer organoids
10.3390/ijms23063203 · ExternalCitation · doi-reference
Prostate organoid cultures as tools to translate genotypes and mutational profiles to pharmacological responses
10.3791/60346 · ExternalCitation · doi-reference
Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer
10.3892/ol.2021.13124 · ExternalCitation · doi-reference
